Tectonic Gets FDA Okay to Begin Clinical Testing for Lead Drug TX45
Tectonic Therapeutic Advances in Pulmonary Hypertension Trials
Express News | Tectonic Therapeutic - Expects to Initiate Global Phase 2 Clinical Trial of Tx45 in Ph-Hfpef in Q3 of 2024, With Topline Results Anticipated in 2026
Express News | Tectonic Therapeutic Announces US Ind Clearance for Lead Program, Tx45
Tectonic Therapeutic Price Target Announced at $49.00/Share by Leerink Partners
Tectonic Therapeutic Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $49
Express News | Tectonic Therapeutic Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $49
Express News | Tectonic Therapeutic Files For Offering Of Up To 2.97M Common Shares By The Selling Stockholders
Express News | Tectonic Therapeutic Inc Files for Offering of up to 2.97 Mln Common Shares by the Selling Stockholders - SEC Filing
Tectonic Therapeutic Announces COO Departure and Severance Terms
Express News | Tectonic Therapeutic Stakeholder Vida Ventures Reports 7% Ownership
Express News | Vv Manager II LLC Reports 7.0% Stake in Tectonic Therapeutic Inc as of June 20 - SEC Filing
Express News | CORRECTION: Tectonic Therapeutic Ticker Is 'TECX'
Express News | Tectonic Therapeutic Shares Are Trading Higher After Piper Sandler Initiated Coverage With an Overweight Rating and Announced a Price Target of $76
Piper Sandler Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $76
Tectonic Therapeutic Price Target Announced at $76.00/Share by Piper Sandler
Piper Sandler Initiates Tectonic Therapeutic at Overweight
Tectonic Therapeutic Analyst Ratings
Express News | Tectonic Therapeutic Inc : TD Cowen Initiates Coverage With Buy Rating
No Data